1Ghidini M, C Pizzo, A Botticelli, JC Hahne, R Passalacqua, G Tomasello, et al. (2019) Biliary tract cancer: current challenges and future prospects. Cancer 291 Manag Res 11: 379-388.

2Razumilava N and GJ Gores (2014) Cholangiocarcinoma. Lancet 383: 2168-2179.

3Bridgewater JA, KA Goodman, A Kalyan, and MF Mulcahy, Biliary Tract (2016) Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. Am Soc Clin Oncol 296 Educ Book 35: 194-203.

4Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33: 1353-1357.

5Rakic M, L Patrlj, M Kopljar, R Klicek, M Kolovrat, et al. (2014) Gallbladder cancer. Hepatobiliary Surg Nutr 3: 221-226.

6Guglielmi A, A Ruzzenente, T Campagnaro, S Pachera, A Valdegamberi, et al. (2009) Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 33: 1247-1254.

7Blechacz B (2017) Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver 11: 13-26.

8Wang Y, J Li, Y Xia, R Gong, K Wang, et al. (2013) Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 31: 1188-1195.

9Hundal R and EA Shaffer (2014) Gallbladder cancer: epidemiology and outcome. Clin 312 Epidemiol 6: 99-109.

10Benson AB, MI D'Angelica, DE Abbott, TA Abrams, SR Alberts, et al. (2019) Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. J Natl Compr Canc Netw 17: 302-310.

11Morizane C, M Ueno, M Ikeda, T Okusaka, H Ishii, and J Furuse (2018) New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin 322 Oncol 48: 703-711.

12Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev 324 Drug Discov 6: 273-286.

13Zhao Y and AA Adjei (2015) Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist 20: 660-673.

14Lee, SH, D Jeong, YS Han, and MJ Baek (2015) Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res 89: 1-8.

15Simone V, O Brunetti, L Lupo, M Testini, E Maiorano, M Simone, et al. (2017) Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. Int J Mol Sci. 18.

16Zheng W, J Ying, Y Zhou, Z Lu, K Min, W Wang, et al. (2019) The Efficacy and Safety of First-line Chemotherapies for Advanced Biliary Tract Cancer: A Network Meta-analysis. J Cancer10: 257-266.

17Larsen FO, A Markussen, LV Diness and D Nielsen (2018) Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study. Oncology 94: 19-24.

18Arkenau HT, J Martin-Liberal, E Calvo, N Penel, MG Krebs, et al. (2018) Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). Oncologist 23:1407-e136.

19Lan CY, Y Wang, Y Xiong, JD Li, JX Shen, YF Li, et al. (2018) Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): phase 2, single-arm, prospective study. Lancet Oncol 19: 1239-1246.

20Li YH, Y Zhou, YW Wang, L Tong, RX Jiang, L Xiao, et al. (2018) Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple- negative breast cancer as third-line therapy: A retrospective study. Medicine 355(Baltimore) 97: e12222.

21Hu X, J Cao, W Hu, C Wu, Y Pan, L Cai, et al. (2014) Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer 14: 820.

22Zhou N, C Liu, H Hou, C Zhang, D Liu, G Wang, K Liu, J Zhu, et al. (2016) Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma. Oncotarget 7: 72373-72379.

23Li F, T Zhu, B Cao, J Wang, and L Liang (2017) Apatinib enhances antitumour the activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Eur J Cancer 84: 184-192.

24Xu J, X Liu, SYang, X Zhang, and Y Shi (2018) Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. Asia Pac J Clin Oncol 14: 264-269.

25Kong Y, L Sun, Z Hou, Y Zhang, P Chen, Y Cui, X Zhu, T Song (2017) Apatinib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget 8: 105596-105605.

26Liu C, W Xing, T Si, H Yu, and Z Guo (2017) Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. Oncotarget 8: 100734-100745.

27Yang C. and S Qin (2018) Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med, 7: 4570-4583.

28Zhu B, J Li, Q Xie, L Diao, L Gai, and W Yang (2018) Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study. Cancer Biol Ther 19: 198-204.

29Liao Z, F Li, C Zhang, L Zhu, Y Shi, G Zhao, et al. (2019) Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety. Exp Mol Med, 51: 24.

30Li F, Z Liao, C Zhang, J Zhao, R Xing, S Teng, J Zhang, et al. (2018) Apatinib as targeted therapy for sarcoma. Oncotarget 9: 24548-24560.

31Lin Y, C Wang, W Gao, R Cui, and J Liang (2017) Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget 8: 42252-42261.

32Feng H, X Cheng, J Kuang, L Chen, S Yuen, M Shi, J Liang, B Shen, et al. (2018) Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer. Cell Death Dis 9: 393 1030.

33Benavides M, A Anton, J Gallego, MA Gomez, A Jimenez-Gordo, A La Casta, et al. (2015) Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol 17: 982-987.

34Lamarca A, RA Hubner, W David Ryder, and JW Valle (2014) Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 25: 2328-38.

35Fornaro L, C Vivaldi, S Cereda, F Leone, G Aprile, S Lonardi, N Silvestris, et al. (2015) Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter surveyand pooled analysis with published data. J Exp Clin Cancer Res 34: 156.

36Peng H, Q Zhang, J Li, N Zhang, Y Hua, L Xu, et al. (2016) Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget 7: 17220-17229.

37Huang M, B Huang, G Li, and S Zeng (2018) Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell. BMC Gastroenterol, 18: 169.

38Wang LY, S Gong, LP Gao, LX Hou, and W He (2018) Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapy: A case report and literature review. Medicine (Baltimore) 97: e13372.

39Brieau B, L Dahan, Y De Rycke, T Boussaha, P Vasseur, et al. (2015) Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Enterologues Oncologues. Cancer 121: 3290-3297.

40Ahn DH and T Bekaii-Saab (2017) Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol 8:293-301.

41Cardinale V, G Carpino, L Reid, E Gaudio, and D Alvaro (2012) Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J Gastrointest Oncol 4: 94-102.

42Chen HX and JN Cleck (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6: 465-477.

43Beauchemin C, JB Johnston, M Lapierre F Aissa and J Lachaine (2015) Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis. Curr Oncol 22: e148-56.

44Forsythe A, D Chandiwana, J Barth, M Thabane, J Baeck, A Shor, and G. Tremblay (2018) Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer? Cancer Manag Res 10:1015-1025.